CCL5 and hepatocellular carcinoma: The expression of both CCL5 and CCR5 in HCC tissues is significantly higher than in healthy liver tissues, and the CCR5 antagonist maraviroc can reverse the CCL5-mediated activation of the PI3K/AKT/mTOR pathway, inhibiting HCC progression in vivo [255].